In the time of COVID-19, the Internet is aflush with expert advice about social distancing. At the same time, raw emotion has driven many to massive trips to the grocery store. In addition to toilet paper, alcohol-based hand sanitizer is the favorite on everybody’s panic-shopping list. The sale of hand sanitizers has gone up almost 500%, in contrast to soap, which has gone up a paltry 70%. So why do experts advise social distancing, and are hand sanitizers the answer to all our problems?READ MORE
Vivli, the Center for Clinical Research Data, recently issued a press release announcing the launch of the COVID-19 portal, designed to enable the sharing of completed interventional treatment trial data. Technology Networks spoke with Julie Wood, Vivli’s Director of Strategy and Operations, to learn more about the COVID-19 portal and discover how researchers can access the data within the portal.
Scientists have discovered a novel overlapping coding sequence in the gene POLG . What does this mean? Is there a "hidden" genome? Technology Networks spoke with researcher Yousuf Khan to find out more.READ MORE
So-called “legacy” PFAS are potentially harmful to health and consequently analysts have been looking to detect them in consumer products such as drinking water. We spoke to Dr Katherine C. Hyland from SCIEX, about sources of PFAS that are contaminating our water system, the hazards posed to consumers and the outlook for detection and prevention strategies.READ MORE
In this article, we review two key questions that remain around the spread of the novel coronavirus SARS-CoV-2.READ MORE
It has been estimated that 60% of the population would need to be infected for herd immunity to be achieved, clearly leading to many deaths. But what is herd immunity and could it realistically be a viable option in tackling the current coronavirus pandemic?READ MORE
Each individual’s genetic makeup is slightly different from everyone else’s, so why are we all receiving the same medicine? To put it simply – the lucrative blockbuster business model, which has previously been the key to pharma success, is no longer viable. In a global and fast-moving world, in order to evolve, it’s time to examine new alternatives to the classic structure.READ MORE
In a bid to meet the increasing demand for quality-controlled, disease-relevant, research-grade iPSC lines, a project began in 2014 to set up the first European Bank of induced Pluripotent Stem Cells (EBiSC).
Here, Technology Networks speaks to Rachel Steeg, a coordinator of EBiSC activities, to discuss phase two of the project and discover some of the benefits it is bringing to the scientific community.